Venture capital fund · 33 deals
Melbourne, VIC
Every published round Brandon Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Brandon Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | 2022, Series B | 3 | 0 | |
| Amaroq Therapeutics | 8 Jul 2021 | 1 | 1 | |
| Ankere | 6 May 2022, Seed | 1 | 1 | |
| Ankere Therapeutics | 3 May 2022, Seed | 1 | 1 | |
| Aravax | 20 Dec 2022, Series B | 2 | 0 | |
| Axelia Oncology | 2 Sep 2026, undisclosed | 1 | 0 | |
| Cincera Therapeutics | 2 Sep 2026, undisclosed | 1 | 0 | |
| Currus Biologics | 5 Jul 2021, Series A | 1 | 0 | |
| Denteric | 26 Sep 2019, Series A | 1 | 0 | |
| EBR Systems | Nov 2021 | 1 | 0 | |
| Elastagen Pty Ltd | Jan 2016, Series B | 1 | 0 | |
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 15 Jun 2021 | 3 | 1 |
| Fibrotech | 10 Feb 2009, Series A | 1 | 0 | |
| Glyscend | 12 Jun 2020, Series A | 1 | 1 | |
| Glyscend, Inc. | Oral polymer drugs mimicking bariatric surgery for metabolic disease | Jun 2020, Series A | 1 | 1 |
| Lumonus | Mar 2026, Series B | 2 | 0 | |
| Mirugen | 14 Aug 2025, Seed | 1 | 0 | |
| Myricx | 2019, Seed | 2 | 1 | |
| Myricx Pharma | 17 Nov 2020, Seed | 1 | 0 | |
| Okogen | Dec 2017, Series A | 1 | 0 | |
| OncoRes Medical | Apr 2022, Series A | 2 | 1 | |
| Pathios Therapeutics | 1 May 2024, Series B | 1 | 0 | |
| Pheon Therapeutics | 28 Sep 2022, Series A | 1 | 1 | |
| Polyactiva | 30 May 2025, Series C | 1 | 1 | |
| Vaxxas | 4 Aug 2011, Series A | 1 | 0 |
Companies Brandon Capital's own portfolio page lists that no published round yet places it in. The page is the source; the round is being looked for.
| Company | Site |
|---|---|
| Aravax Pty Ltd | - |
| AstronauTx | - |
| Azura Ophthalmics | - |
| CatalYm | - |
| Certa Therapeutics | - |
| George Medicines | - |
| Longas | - |
| MycRx | - |
| NRG Therapeutics | - |
| Perx | - |
| PKG Health (Global Kinetics) | - |
| Q-Sera | - |
| Respirion | - |
| Spinifex | - |
Fund closes reported for Brandon Capital, as distinct from the investments it has made.
| Fund | Announced | Committed | Target | Close | Sources |
|---|---|---|---|---|---|
| Fund Six | 24 Jul 2025 | $430m | - | Final | Forbes Australia, @AuManufacturing, Brandon Capital portfolio |
| Brandon Capital Fund VI | 4 Jun 2024 | $270m | - | Interim | Brandon Capital, Brandon Capital portfolio |
| the first MRCF fund | 2007 | $30m | - | - | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Investors that coverage says has money in a fund Brandon Capital runs. This is a stake in the fund, not in any company the fund has backed.
Companies Brandon Capital has backed that another company then bought. An exit for the holding, not a deal Brandon Capital did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Myricx | Novartis | Acquisition | Jul 2026 | ≤$2.2b |
| Elastagen Pty Ltd | Allergan plc | Acquisition | 7 Feb 2018 | $350m |
| Fibrotech | Shire plc | Acquisition | 2014 | US$75m ($85.6m) |
Stories naming Brandon Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.
Brandon Capital is welcoming a $60 million commitment of public money via the NRF, earmarked for the firm's life-science investing.
Brandon Capital has put roughly $60 million of National Reconstruction Fund money into ten biotech companies and warns R&D tax changes would hurt deep tech; portfolio company Myricx Bio went to Novartis.
Also australiatimes.com
Brandon Capital's blog interviews Denteric's operating chief about its gingipain-targeting therapy for periodontitis, trial progress, and its origins in University of Melbourne oral health research.
The US medicines regulator has granted Fast Track designation to Aravax's peanut-allergy immunotherapy PVX108, easing its development path; the Melbourne-based biotech expects Phase 2 data later in 2026.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Brisbane radiopharmaceutical developer AdvanCell has closed an oversubscribed Series D round, led by Ally Bridge Group and Alpha Wave with several institutional investors returning, to fund late-stage prostate cancer trials and US manufacturing.
Novartis is acquiring London biotech Myricx Bio for US$1.1 billion upfront plus milestone payments, handing Melbourne venture firm Brandon Capital a record return on the startup it seeded in 2019.
Also Forbes Australia
Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.
Brandon Capital's blog profiles Respirion, interviewing founders Barry Clements and Matt Callahan plus investment manager Helga Mikkelsen about the company's inhaled cystic fibrosis therapy, now in a Phase 2a trial.
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Q-Sera's rapid-clotting blood tube technology has gone to market in Japan via Terumo's VenoJect II launch; the Melbourne startup's backers include MRCF, Uniseed and the UniQuest Extension Fund.
A weekly roundup detailing new funding rounds for six Australian startups: Lyka, PlasmaLeap, Firmable, Veyor, Lumonus and Future Minds Network, with investors and round details.
Investible announces it backed Lumonus' A$28 million round with three co-investors, the first deal from its new early-stage fund; Lumonus builds AI software that automates cancer clinic workflows.
Perth-based OncoRes Medical has secured $27 million from Brandon Capital's BB6 Fund, Morgans, Radar Ventures and others to advance its Elora breast-surgery imaging device through an Australian clinical trial toward FDA approval.
Also oncoresmedical.com
Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.
Digital health firm Perx Health splits in two: Clutch has bought its US business and its Australian arm will combine with Navigator Group, with founders moving to roles at the buyers.
Also Dealroom
Profile tracing Sara Prickett's path from UK labs to co-founding Aravax, the peanut-allergy biotech Brandon Capital backed, as its Phase II trial nears readout in mid-2026.
Weekly funding roundup covering eight raises totalling over $113 million across aerospace, biotech, materials, health and software, plus a pharmacy firm's acquisition out of administration.
Weekly roundup of eight trans-Tasman startup raises worth a combined $113 million-plus, alongside Joe Zhou's buyout of StrongRoom AI from administrators.
Brandon BioCatalyst has named Peter Beattie its chair as Bill Ferris retires, with Andrew Nash joining the board and Ross King becoming deputy; manager Brandon Capital's newly raised $439 million fund was noted.
Mirugen, a Melbourne biotech spun out of an eye research institute, has closed a A$4.5m seed round with three backers and hired Charlotte Casebourne Stock as chair and acting chief executive.
Also cera.org.au·Brandon BioCatalyst portfolio·insightnews.com.au
Australia's NRFC has injected $150m into Brandon Capital's sixth life-science vehicle, lifting it to a $439m close; past NRFC cheques to local deep-tech firms are also recapped.
Brandon Capital has completed a A$439 million final close for its sixth life sciences fund, bringing the National Reconstruction Fund Corporation and WA Government in alongside backers such as HESTA, Hostplus, CSL and QIC.
Australian biotech PolyActiva has raised A$40 million in Series C funding to advance its PA5108 ocular implant and PREZIA platform, backed by the National Reconstruction Fund Corporation and Brandon Capital.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·SmartCompany·polyactiva.com·Startup Daily·ophthalmologybreakingnews.com·Forbes Australia
Biotech PolyActiva has banked a Series C round led by the National Reconstruction Fund with Brandon Capital, funding late-stage trials of its dissolvable glaucoma implant and a consolidated Melbourne site.
Also Startup Daily
Citing AFR reporting, the publisher relays that the federal reconstruction investor is set to announce a stake in a glaucoma treatment developer, alongside venture co-funding, and plugs its June funding panel.
A profile of Brandon Capital partner Chris Smith, tracing his path from immunology research and a Cambridge postdoc into biotech investing, with resilience lessons drawn from equestrian sport and companies Aravax and ENA Respiratory.
Profile of OncoRes Medical CEO Katharine Giles, tracing her path from surgeon to venture investor and her leadership of the Western Australian medtech firm developing a handheld device for precise breast cancer surgery.
A profile of ENA Respiratory traces its INNA-051 immune-boosting nasal spray from an accidental lab finding to Phase 2 trials, noting AUD 49 million in funding, a US Defence contract and Flu Lab investment.
Profile of Australian biotech startup Proxima Bio, covering its founding, an early MRFF grant through the CUREator program, Brandon Capital's guidance, and a later larger investment that grew the team.
Vaxxas has finished enrolling 258 volunteers in its Phase I trial of a needle-free HD-MAP avian flu vaccine, funded by a US BARDA contract, with early findings due mid-2025.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas has filled its 258-person Phase I trial of a needle-free avian flu vaccine patch, run under a US$28.5 million US government contract; the post also recounts the company's early backing.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.
Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.
Vaxxas has won the concept stage of BARDA's Patch Forward Prize, earning US$2 million (A$3.2 million) to progress its microarray patch vaccine platform alongside the University of Queensland's BASE facility.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Vaxxas wins US$2 million as a concept-stage winner of BARDA's prize to advance its skin-patch vaccine platform with UQ's BASE facility; the article also recalls early backing by OneVentures, Brandon Capital and HealthCare Ventures.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·@AuManufacturing·Business News Australia
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.